Skip to main content

 Scientific publications

Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer.

Authors : Genot-Klastersky MT, Paesmans M, Ameye L, Kayumba A, Beauvois S, Dragan T, Van Gestel D, Lalami Y, Klastersky JA
Year : 2019
Journal : Support Care Cancer

Activity and safety of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).

Authors : Machiels JP, Bossi P, Menis J, Lia M, Fortpied C, Liu Y, Lhommel R, Lemort M, Schmitz S, Canevari S, De Cecco L, Guzzo M, Bianchi R, Quattrone P, Crippa F, Duprez T, Lalami Y, Quiriny M, de Saint-Aubain de Somerhausen N, Clement PM, Coropciuc R, Hauben E, Licitra LF
Year : 2018
Journal : Ann Oncol
Volume : 29(4)
Pages : 985-991

Calcitonin and Carcinoembryonic Antigen for the Diagnosis and Management of Medullary Thyroid Carcinoma. in : Luca Giovanella, Editor. Atlas of Thyroid and Neuroendocrine Tumor Markers. Springer

Authors : Costante G, Lalami Y, Jungels C, Awada A
Year : 2018
Journal : Book
Volume : -
Pages : 133-150

Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.

Authors : Lalami Y, Klastersky J
Year : 2017
Journal : Crit Rev Oncol Hematol
Volume : 120
Pages : 163-179

Unusual presentation of nasopharyngeal carcinoma with rectal metastasis.

Authors : Vogel M, Kourie HR, Piccart-Gebhart M, Lalami Y
Year : 2017
Journal : World J Clin Cases
Volume : 5
Pages : 183-186

Nouvelles promesses de l'immunothérapie pour les carcinomes épidermoïdes de la tête et du cou : entre rationnel scientifique et efficacité clinique

Authors : Lalami Y
Year : 2017
Journal : Nucl Recept Signal
Volume : 10(7)
Pages : 59-65

A Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early FDG PET-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.

Authors : Lalami Y, Garcia C, Flamen P, Ameye L, Paesmans M, Awada A
Year : 2016
Journal : Head Neck
Volume : 38(3)
Pages : 347-54

Clinical research in febrile neutropenia in cancer patients:Past achievements and perspectives for the future

Authors : Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L
Year : 2016
Journal : World J Clin Infect Dis
Volume : 6(3)
Pages : 37-60

Nasopharyngeal adenoid cystic carcinoma, a rare but highly challenging disease with unmet therapeutic needs: A case-report and review of the literature].

Authors : Afani L, Errihani H, Benchafai I, Lalami Y
Year : 2016
Journal : Cancer Radiother
Volume : 20(5)
Pages : 400-4

Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice.

Authors : Lalami Y, Awada A
Year : 2016
Journal : Cancer Treat Rev
Volume : 43
Pages : 113-23

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.

Authors : Machiels JP, Specenier P, Krauß J, Dietz A, Kaminsky MC, Lalami Y, Henke M, Keilholz U, Knecht R, Skartved NJ, Horak ID, Pamperin P, Braun S, Gauler TC
Year : 2015
Journal : Cancer Chemother Pharmacol
Volume : 76(1)
Pages : 13-20

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Year : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

Clinical trial design in head and neck cancer: from past experiences to future perspectives.

Authors : de Castro G Jr, Henrique dos Anjos C, Lalami Y, Awada A
Year : 2012
Journal : Clinical Investigation
Volume : 2(5)
Pages : 473-481

EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

Authors : Lalami Y, Specenier PM, Awada A, Lacombe D, Liberatoscioli C, Fortpied C, El-Hariry I, Bogaerts J, Andry G, Langendijk HJ, Vermorken JB
Year : 2012
Journal : Radiother Oncol
Volume : 105(2)
Pages : 238-40

Thérapies biologiques ciblées et cancer thyroïdien récidivant : enfin un standard thérapeutique ?

Authors : Lalami Y
Year : 2012
Journal : Onco-Hémato
Volume : 6(5)
Pages : 45-51

Recurrent thyroid cancer: a molecular-based therapeutic breakthrough.

Authors : Lalami Y, Awada A
Year : 2011
Journal : Curr Opin Oncol
Volume : 23(3)
Pages : 235-40